US panel sees no major cardiovascular risk with saxagliptin
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb/AstraZeneca's investigational diabetes agent Onglyza (saxagliptin) does not pose an unacceptable cardiovascular risk, but the companies should nevertheless conduct a large post-approval CV safety study of the DPP-4 inhibitor, the US FDA's outside experts say.